Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Beyond Monoclonal Antibodies: Cutting-Edge Approaches to Targeted Therapy" in Drug Design, Development and Therapy.
Monoclonal antibodies have revolutionized the development of targeted therapies, enabling the precise and selective targeting of disease biomarkers, leading to the development of more effective therapies. While over 100 monoclonal antibodies have been approved by the FDA, recent advancements in molecular engineering have greatly expanded the array of engineered proteins that have been approved by regulatory bodies or are currently being evaluated in clinical trials. As a result, the development of targeted therapies has become more versatile and sophisticated, offering new hope for patients with previously untreatable diseases.
This Article Collection aims to highlight the latest advancements in antibody and protein engineering, including design strategies, preclinical screening methods and their translation into clinical practice. Specifically, this Collection will cover:
1. Design and selection of synthetic binders, including but not limited to antibodies, affibodies, monobodies, nanobodies, adhirons, ubiquitin variants, DARPin, peptidomimetics, and cytokines.
2. Antibody engineering, such as the development of bispecific antibodies, antibody-drug conjugates, alternative modalities, and engineered Fc regions.
3. Genetically encoded protein degraders and their impact on targeted protein degradation.
4. From the bench to the bedside: showcasing therapeutic applications of novel biologics for the treatment of cancer, autoimmune diseases, and viral infections.
By highlighting the latest advancements in antibody and protein engineering, we hope to provide insights into how these innovations are changing the landscape of drug development and therapy.
Please submit your manuscript on our website, quoting the promo code ZLRGC to indicate that your submission is for consideration in this Article Collection.
Guest Advisor Dr. Gianluca Veggiani is a Research Assistant Professor in nano-immunoengineering at the Department of Pathobiological Sciences of Louisiana State University. He joined the university in 2022 and his current work focuses on developing high-throughput methods for synthetic biology, vaccines, and novel cancer diagnostics and therapeutics. During his postdoctoral work at the University of Toronto, Dr. Veggiani developed molecular probes for detection and modulation of post-translational modifications and efficient gene editing. He also pioneered the development of molecular superglues for protein polymerization, enhanced T-cell activation, and sensitive circulating tumor cell isolation during his doctoral work at the University of Oxford.
Disclosure Statement: Guest Advisor Dr. Veggiani declares no conflict of interest regarding this work.
